Market Overview

UPDATE: Jefferies Reiterates Buy Rating, Lowers PT on Myriad Genetics on New Medicare Code Values

Share:
Related MYGN
Worst Performing Industries For February 3, 2016
Myriad Genetics, Thermo Fisher Two Top Life Science & Diagnostic Picks At Deutsche Bank

In a report published Monday, Jefferies reiterated its Buy rating on Myriad Genetics (NASDAQ: MYGN), but lowered its price target from $33.00 to $31.00.

Jefferies noted, “Noridian, MYGN's designated Medicare contractor, released the highly anticipated new molecular pathology reimbursement codes for CY13. The new codes suggest an 8% decrease and a 14% increase for MYGN's BRACAnalysis and COLARIS tests, respectively, relative to current commercial reimbursement rates. We are trimming our FY14 EPS forecast to $1.60 (from $1.65) on the disclosure. Our PT moves to $31 (from $33) on lower cash flow forecasts.”

Myriad Genetics closed on Friday at $25.46.

Latest Ratings for MYGN

DateFirmActionFromTo
Jan 2016Deutsche BankInitiates Coverage onBuy
Jan 2016Avondale PartnersInitiates Coverage onMarket Outperform
Dec 2015Goldman SachsUpgradesSellNeutral

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (MYGN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters